HRT: Replacing the Hormones of Menopause
At menopause the ovaries stop making estrogen, and the sudden drop causes hot flushes, sleep problems, and long-term effects on bone. Hormone replacement therapy simply gives some of that estrogen back — but with one crucial rule involving the womb that turns a subtle piece of biology into a safety essential every clinician must know.
Menopause is when a woman's ovaries wind down and stop producing estrogen and progesterone. The falling estrogen brings the familiar symptoms: hot flushes and night sweats, disturbed sleep, mood changes, and vaginal dryness. Over the longer term, the loss of estrogen also speeds up bone loss, raising the risk of osteoporosis. Hormone replacement therapy (HRT) is exactly what its name says — replacing the hormones the ovaries no longer make, chiefly estrogen, to relieve those symptoms. It's a straightforward idea, but the way it's given hinges on one anatomical detail that changes everything: whether or not the woman still has a womb.
The golden rule: estrogen needs a progestogen if there's a womb
Unopposed estrogen overstimulates the womb lining. Here's the pivotal safety point. Estrogen stimulates the lining of the womb (the endometrium) to grow. If you give estrogen on its own ('unopposed estrogen') to a woman who still has her womb, that constant stimulation can build the lining up abnormally and raise the risk of endometrial cancer. The protective fix is to add a progestogen, which opposes estrogen's effect on the lining and keeps it safe. So the rule is simple and absolute: a woman WITH a womb must receive combined HRT (estrogen plus a progestogen); a woman who has had a hysterectomy (no womb) can safely take estrogen alone, because there's no endometrium to protect. This single principle — 'estrogen-only only if there's no uterus' — is one of the most important and most-tested facts in this whole topic, and it's a direct echo of the same logic used in the combined contraceptive pill.
Benefits, risks, and how to weigh them
HRT is very effective at relieving menopausal symptoms — especially hot flushes — and it helps protect bone against osteoporosis. Against these benefits sit some risks that depend on the type, dose, route and the woman's age. Like the combined pill, oral estrogen carries a small increased risk of blood clots (venous thromboembolism), and this is one reason transdermal estrogen — a patch or gel absorbed through the skin — is often preferred, as it appears to carry less clot risk by avoiding first-pass through the liver (a nice callback to the pharmacokinetics chapter). Combined HRT is associated with a small increase in breast cancer risk that relates to duration of use, while stroke risk is a consideration particularly in older women or with oral preparations. The modern approach is individualised: for a woman with troublesome symptoms starting HRT near the time of menopause, the benefits usually outweigh the risks, using the lowest effective dose for as long as it's helpful and reviewing regularly. It's a genuine risk–benefit conversation, not a blanket yes or no — but the womb rule is never optional.
- Menopause = ovaries stop making estrogen → hot flushes, sleep/mood changes, bone loss.
- HRT replaces estrogen to relieve symptoms and protect bone.
- GOLDEN RULE: woman WITH a womb needs estrogen + progestogen (to protect the endometrium).
- No womb (hysterectomy) → estrogen alone is safe. Unopposed estrogen risks endometrial cancer.
- Risks: clots (transdermal preferred to reduce this), small breast cancer/stroke risk; individualise.
The womb rule in HRT and the clot rule in the contraceptive pill are the two facts that make sex-hormone pharmacology click, and both come from the same place: estrogen's biology. Estrogen makes the endometrium grow, so if a uterus is present you must always add a progestogen to keep that growth in check — leave it 'unopposed' and you risk endometrial cancer. Estrogen also promotes clotting, so its use is tempered wherever clot risk is already high. Learn those two consequences of estrogen — it builds the womb lining, and it favours clots — and you can reason your way through most of contraception and HRT without memorising tables.
- Giving estrogen-only HRT to a woman who still has her uterus — endometrial cancer risk.
- Overlooking clot risk with oral estrogen — transdermal often reduces it.
- Treating HRT as all-benefit or all-risk — it's an individualised risk–benefit decision.
- Ignoring symptom severity and timing — benefits are greatest starting near menopause.
A menopausal woman who still has her uterus is starting HRT. What must be included?
- Menopause: estrogen falls → hot flushes, bone loss; HRT replaces estrogen.
- Womb present → must add a progestogen (protects endometrium); no womb → estrogen alone.
- Risks: clots (transdermal lowers this), small breast cancer/stroke risk — individualise.
- Same estrogen biology (grows endometrium, favours clots) underlies HRT and the pill.
- Katzung BG. Basic & Clinical Pharmacology — The Gonadal Hormones & Inhibitors.
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Estrogens & progestins.
- NICE / NAMS — Menopause: diagnosis and management (HRT).
- Whalen K. Lippincott Illustrated Reviews: Pharmacology — Estrogens & hormone replacement.
